Equities

STAAR Surgical Co

STAAR Surgical Co

Actions
Health CareMedical Equipment and Services
  • Price (USD)26.63
  • Today's Change0.31 / 1.18%
  • Shares traded507.11k
  • 1 Year change-20.65%
  • Beta0.5801
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

  • Revenue in USD (TTM)341.22m
  • Net income in USD21.78m
  • Incorporated1986
  • Employees1.06k
  • Location
    STAAR Surgical Co1911 Walker AveMONROVIA 91016United StatesUSA
  • Phone+1 (626) 303-7902
  • Fax+1 (302) 636-5454
  • Websitehttps://www.staar.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CeriBell Inc-100.00bn-100.00bn898.43m----------------0.336------------------------2.14--0.6304--74.47--20.72------
Bioventus Inc555.06m-39.48m934.09m1.03k--6.28--1.68-0.6172-0.61728.681.830.70231.954.73572,227.80-6.47-5.52-9.13-7.2767.0068.25-9.22-10.940.98661.130.6725--0.04459.936.91--23.51--
Owens & Minor, Inc.10.66bn-48.79m943.04m13.70k--1.084.260.0885-0.6346-0.6346139.2711.352.097.2615.86778,172.30-0.95611.32-1.492.0720.7216.48-0.45760.56140.45192.030.68310.7983.801.87-284.47--25.91--
Pulse Biosciences Inc0.00-46.13m991.65m56.00--12.53-----0.8069-0.80690.001.290.00----0.00-58.03-93.21-62.84-104.99-------12,332.25----0.00---100.00--27.85---15.20--
BioLife Solutions Inc118.41m-26.44m1.17bn409.00--3.61--9.89-0.5826-1.012.597.040.29871.695.58289,513.40-6.67-13.76-7.37-15.0446.1536.76-22.33-42.991.78-4.030.0614---11.4348.6552.49--86.35--
Artivion Inc384.90m-846.00k1.18bn1.50k--3.8551.373.05-0.0235-0.02359.257.270.48791.685.50256,599.30-0.1079-2.20-0.1242-2.3664.5365.51-0.2211-5.341.331.100.51--12.826.14-60.09--5.13--
Establishment Labs Holdings Inc153.07m-70.61m1.19bn933.00--36.43--7.78-2.58-2.585.571.170.55340.79162.51168,580.40-25.53-33.22-31.21-41.1265.0864.73-46.13-43.192.29-4.510.856--2.1321.96-4.38--69.16--
STAAR Surgical Co341.22m21.78m1.31bn1.06k60.783.0647.443.850.43810.43816.908.690.67632.033.15323,128.804.326.774.927.9078.7376.896.389.165.38--0.00020.0013.3721.07-46.1833.8551.95--
Adapthealth Corp3.26bn-217.76m1.33bn10.70k--0.87768.070.4079-1.64-1.6424.2311.270.709621.158.45304,912.50-4.57-4.34-5.14-4.8919.0318.28-6.44-6.470.99512.290.5757--7.73---1,169.99------
Evolent Health Inc2.46bn-104.23m1.35bn4.70k--1.2892.720.5482-0.9129-0.912921.5510.660.953--6.14524,309.40-2.79-9.60-3.58-12.5915.9624.50-2.93-13.66---0.55950.3285--45.2625.65-660.71---6.18--
Myriad Genetics, Inc.823.60m-116.00m1.38bn2.70k--1.88--1.67-1.30-1.309.218.040.73859.916.84305,037.00-10.40---12.43--69.15---14.08--1.73-105.000.0506--11.03---135.09------
Inmode Ltd423.75m153.67m1.41bn581.0010.012.079.143.331.851.855.048.920.52391.5810.15729,339.1019.0031.3220.7735.6481.6484.4636.2639.659.91--0.000.008.3237.4922.5454.6513.10--
Alphatec Holdings Inc572.74m-177.87m1.45bn839.00------2.53-1.27-1.274.080.15460.80891.117.73682,644.80-25.12-30.97-32.00-39.4769.4766.02-31.06-46.221.15-3.660.9596--37.4539.38-23.36--67.92--
10X Genomics Inc629.74m-182.55m1.61bn1.26k--2.23--2.55-1.53-1.535.265.970.66772.406.72500,193.00-19.36-25.52-21.99-29.0566.6375.88-28.99-48.534.12--0.00--19.8133.43-53.67--49.15--
AtriCure Inc447.57m-38.92m1.74bn1.20k--3.74--3.89-0.8322-0.83229.569.540.73651.638.41372,977.50-6.40-3.72-7.35-4.1074.7974.36-8.70-7.642.59-13.760.1194--20.8414.6434.49--46.56--
Data as of Nov 21 2024. Currency figures normalised to STAAR Surgical Co's reporting currency: US Dollar USD

Institutional shareholders

63.43%Per cent of shares held by top holders
HolderShares% Held
Broadwood Capital, Inc.as of 30 Sep 202410.77m21.89%
BlackRock Fund Advisorsas of 30 Sep 20246.97m14.17%
The Vanguard Group, Inc.as of 30 Sep 20245.40m10.98%
SSgA Funds Management, Inc.as of 30 Sep 20241.94m3.95%
Baillie Gifford & Co.as of 30 Sep 20241.46m2.97%
Geode Capital Management LLCas of 30 Sep 20241.17m2.39%
Palo Alto Investors LPas of 30 Sep 20241.09m2.22%
Citadel Advisors LLCas of 30 Sep 2024858.88k1.75%
Millennium Management LLCas of 30 Sep 2024842.22k1.71%
Geneva Capital Management LLCas of 30 Sep 2024695.42k1.41%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.